TABLE 4.

ALT values for subjects in this study

Patient no.	Dose (mg/kg)	Serum ALT value (U/liter) at:
		Baselinea	Day 7	Day 14	Day 28	Day 42	Day 56
1	0.05	67	66	73	65	61	66
2	0.05	54	58	56	38	31	40
3	0.05	88	39	78	66	82	88
4	0.05	40	40	37	38	31	35
5	0.05	91	98	102	91	86	—b
6	0.05	57	61	95	100	89	95
7	0.05	46	44	44	41	43	43
8	0.05	53	56	46	52	64	65
9	0.05	155	131	—	—	—	—
10	0.05	96	119	99	75	84	68
11	0.05	64	80	58	54	65	58
12	0.05	79	81	80	78	80	98
Mean		74	73	70	63	65	66
Median		66	64	73	65	65	66
SD		31	30	23	21	22	23
13	0.10	39	38	35	37	41	31
14	0.10	158	172	137	122	135	135
15	0.10	45	37	48	49	51	45
16	0.10	53	58	59	42	44	36
17	0.10	76	83	87	93	—	—
18	0.10	75	79	70	72	69	69
19	0.10	81	90	95	137	94	122
Mean		75	80	76	79	72	73
Median		75	79	70	72	60	57
SD		40	46	34	40	36	45

^aSerum ALT results as well as plasma HCV RNA results obtained at the prescreening visit (within 7 days of baseline) and on the day of treatment initiation were averaged in order to obtain the baseline value. 

^b—, Patient discontinued study medication.